# Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue

> **NCT03199963** · PHASE3 · TERMINATED · sponsor: **BHR Pharma, LLC** · enrollment: 223 (actual)

## Conditions studied

- Mammographic Breast Density

## Interventions

- **DRUG:** 4-OH tamoxifen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03199963
- **Lead sponsor:** BHR Pharma, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-21
- **Primary completion:** 2019-01-14
- **Final completion:** 2019-04-23
- **Target enrollment:** 223 (ACTUAL)
- **Why stopped:** Administrative - change in development strategy
- **Last updated:** 2022-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03199963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03199963, "Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03199963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*